APO-CARVEDILOL TABLET Canada - English - Health Canada

apo-carvedilol tablet

apotex inc - carvedilol - tablet - 3.125mg - carvedilol 3.125mg - beta-adrenergic blocking agents

APO-CARVEDILOL TABLET Canada - English - Health Canada

apo-carvedilol tablet

apotex inc - carvedilol - tablet - 6.25mg - carvedilol 6.25mg - beta-adrenergic blocking agents

APO-CARVEDILOL TABLET Canada - English - Health Canada

apo-carvedilol tablet

apotex inc - carvedilol - tablet - 12.5mg - carvedilol 12.5mg - beta-adrenergic blocking agents

APO-CARVEDILOL TABLET Canada - English - Health Canada

apo-carvedilol tablet

apotex inc - carvedilol - tablet - 25mg - carvedilol 25mg - beta-adrenergic blocking agents

CARVEDILOL- carvedilol tablet United States - English - NLM (National Library of Medicine)

carvedilol- carvedilol tablet

cipla usa inc. - carvedilol (unii: 0k47ul67f2) (carvedilol - unii:0k47ul67f2) - carvedilol 3.125 mg - carvedilol tablets are indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ace inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization [see drug interactions (7.4), clinical studies (14.1)] . carvedilol tablets are indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40% (with or without symptomatic heart failure) [see clinical studies (14.2)] . carvedilol tablets are indicated for the management of essential hypertension [see clinical studies (14.3, 14.4)] . it can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [see drug interactions (7.2)] . carvedilol is contraindicated in the following conditions: - bronchial asthma or related bronchospastic conditions. deaths from status